1. The effects of the
nitric oxide (
NO) synthase inhibitor
N(G)-nitro-L-arginine methyl ester (
L-NAME) on
anaphylaxis-induced venoconstriction were examined in rat isolated livers perfused with blood-free solutions in order to clarify the role of NO in anaphylactic venoconstriction. 2. Rats were sensitized with
ovalbumin (1 mg) and, 2 weeks later, livers were excised and perfused portally in a recirculating manner at a constant flow with
Krebs'-Henseleit solution. The
antigen (
ovalbumin; 0.1 mg) was injected into the reservoir 10 min after pretreatment with
L-NAME (100 micromol/L) or D-NAME (100 micromol/L) and changes in portal vein pressure (Ppv), hepatic vein pressure (Phv) and perfusate flow were monitored. In addition, concentrations of the stable metabolites of NO ( and ) were determined in the perfusate using an HPLC-Griess system. 3. The
antigen caused hepatic venoconstriction, as evidenced by an increase in Ppv from a mean (SEM) baseline value of 7.7 +/- 0.1 cmH2O to a peak of 21.4 +/- 1.1 cmH2O at 3 min in D-NAME-pretreated livers. Pretreatment with
L-NAME augmented anaphylactic venoconstriction, as reflected by a higher Ppv (27.4 +/- 0.8 cmH2O) after
antigen than observed following D-NAME pretreatment. The addition of
L-arginine, a precursor for the synthesis of NO, reversed the augmentation of anaphylactic venoconstricion by
L-NAME. This suggests that hepatic
anaphylaxis increased the production of NO, which consequently attenuated anaphylactic venoconstriction. However, perfusate NOx levels did not increase significantly after
antigen in livers pretreated with either
L-NAME or D-NAME. 4. In conclusion,
L-NAME potentiates rat anaphylactic hepatic venoconstriction, suggesting that NO contributes to the attenuation of the venoconstriction. However, this functional evidence was not accompanied by corresponding changes in perfusate NOx concentrations.